Evidence map›Paper›PMID 37719019›Full record

ArticleFrontiers in oncology2023

MiR-4270 acts as a tumor suppressor by directly targeting Bcl-xL in human osteosarcoma cells.

Clément Veys, Flavie Boulouard, Abderrahim Benmoussa, Manon Jammes, Emilie Brotin, Françoise Rédini, Laurent Poulain, Nicolas Gruchy, Christophe Denoyelle, Florence Legendre and 1 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Clément VeysNormandie Univ., UNICAEN, BIOTARGEN, Caen, France.
Flavie BoulouardNormandie Univ., UNICAEN, BIOTARGEN, Caen, France.
Abderrahim BenmoussaNormandie Univ., UNICAEN, BIOTARGEN, Caen, France.
Manon JammesNormandie Univ., UNICAEN, BIOTARGEN, Caen, France.
Emilie BrotinNormandie Univ., UNICAEN, Federative Structure Normandie Oncology, US Platon, ImpedanCELL Platform, Caen, France.
Françoise RédiniUMR 1238 Phy-Os "Bone Sarcomas and Remodeling of Calcified Tissues", INSERM, Nantes University, Nantes, France.
Laurent PoulainNormandie Univ., UNICAEN, INSERM U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.
Nicolas GruchyNormandie Univ., UNICAEN, BIOTARGEN, Caen, France.
Christophe DenoyelleNormandie Univ., UNICAEN, Federative Structure Normandie Oncology, US Platon, ImpedanCELL Platform, Caen, France.
Florence LegendreNormandie Univ., UNICAEN, BIOTARGEN, Caen, France.
Philippe GaleraNormandie Univ., UNICAEN, BIOTARGEN, Caen, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chondrosarcomas and osteosarcomas are malignant bone tumors with a poor prognosis when unresectable or metastasized. Moreover, radiotherapy and chemotherapy could be ineffective. MiRNAs represent an alternative therapeutic approach. Based on high-throughput functional screening, we identified four miRNAs with a potential antiproliferative effect on SW1353 chondrosarcoma cells. Individual functional validations were then performed in SW1353 cells, as well as in three osteosarcoma cell lines. The antiproliferative and cytotoxic effects of miRNAs were evaluated in comparison with a positive control, miR-342-5p. The cytotoxic effect of four selected miRNAs was not confirmed on SW1353 cells, but we unambiguously revealed that miR-4270 had a potent cytotoxic effect on HOS and MG-63 osteosarcoma cell lines, but not on SaOS-2 cell line. Furthermore, like miR-342-5p, miR-4270 induced apoptosis in these two cell lines. In addition, we provided the first report of Bcl-xL as a direct target of miR-4270. MiR-4270 also decreased the expression of the anti-apoptotic protein Mcl-1, and increased the expression of the pro-apoptotic protein Bak. Our findings demonstrated that miR-4270 has tumor suppressive activity in osteosarcoma cells, particularly through Bcl-xL downregulation.

Indexed as

apoptosisBcl-XLchondrosarcomamiR-342-5pmiR-4270osteosarcoma

Identifiers

PMID37719019
PMCPMC10501397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.